Press Releases

May 12, 2021
Webinar Scheduled for 2:30 PM PT / 5:30 PM ET SOUTH SAN FRANCISCO, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer will discuss progress on
May 05, 2021
CD19 Program Highlights Data from the ALLO-501 ALPHA Study and ALLO-501A ALPHA2 Study to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Longer Term Follow-Up from the ALPHA Study and Consolidation Dosing in Both ALPHA and ALPHA2 Study to be Included Allogene to Host
Apr 27, 2021
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today
Apr 21, 2021
RMAT Designation Follows Proof-of-Concept Data from ALLO-715 UNIVERSAL Trial in Heavily Pretreated, Refractory Multiple Myeloma Patients UNIVERSAL Trial Demonstrated for the First Time that an Allogeneic CAR T Therapy Directed at BCMA Can Achieve Clinical Responses While Eliminating the Need for
Apr 19, 2021
TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T™ Cells Phase 1 IGNITE Trial Expected to Begin in Mid-2021 ALLO-605 is One of Allogene’s Three Strategies to Target BCMA for the Treatment of Patients
Apr 12, 2021
SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn. , April 12, 2021 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer, and SpringWorks
Apr 10, 2021
Proprietary TurboCAR Technology Platform Allows Cytokine Activation Signaling to be Selectively Engineered into AlloCAR T™ Cells New TurboCAR Constructs Can Be Induced by Binding To PDL1/2, Making Cytokine Activation Dependent Upon the Tumor Microenvironment and Overcoming PDL1/2 Inhibition Results
Displaying 1 - 10 of 13
Print Page
Email Alerts
RSS Feeds
Investor Contacts